A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial

Ranjana H. Advani, Stephen M. Ansell, Mary J. Lechowicz, Anne W. Beaven, Fausto Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine Foss, Steven Horwitz, Barbara Pro, Lauren C. Pinter-Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose

Research output: Contribution to journalArticle

43 Scopus citations

Fingerprint Dive into the research topics of 'A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial'. Together they form a unique fingerprint.

Medicine & Life Sciences